← Back to Search

Anti-metabolites

Docetaxel With/Without Oblimersen for Lung Cancer

Phase 2 & 3

Waitlist Available

Research Sponsored by Genta Incorporated

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Relapsed or refractory disease

No uncontrolled diabetes mellitus

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will compare the effectiveness of docetaxel with or without oblimersen in treating patients with relapsed or refractory non-small cell lung cancer.

Who is the study for?

This trial is for adults over 18 with non-small cell lung cancer that's come back or hasn't responded to treatment. They should have had only one prior chemo regimen, be in fairly good health, not pregnant, and able to use contraception. People with severe diseases, certain allergies, uncontrolled conditions like heart failure or diabetes, active infections or cancers other than NSCLC can't join.Check my eligibility

What is being tested?

The study is testing if adding a drug called Oblimersen to the chemotherapy drug Docetaxel helps more in treating non-small cell lung cancer compared to using Docetaxel alone. Patients are randomly assigned to either get both drugs or just Docetaxel.See study design

What are the potential side effects?

Docetaxel can cause side effects like low blood counts leading to infection risk, allergic reactions, hair loss and nail changes. Oblimersen might increase these effects by making cells more sensitive to chemotherapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My condition has returned or didn't respond to treatment.

Select...

My diabetes is under control.

Select...

I do not have any major health issues.

Select...

I do not have any disabilities that would stop me from joining the study.

Select...

My cancer can be measured and has not been treated with radiation.

Select...

I have had one chemotherapy treatment for my cancer.

Select...

I am 18 years old or older.

Select...

I am able to get out of my bed or chair and move around.

Select...

My liver functions are within normal limits and I don't have chronic hepatitis or cirrhosis.

Select...

My kidney function, measured by creatinine, is within normal limits.

Select...

My heart condition does not severely limit my daily activities.

Select...

I do not have severe lung disease or need oxygen due to lung surgery.

Select...

I do not have HIV, active infections, or autoimmune diseases.

Select...

I do not have any other active cancer.

Select...

I do not have seizures that my medication cannot control.

Select...

I do not have severe numbness or pain in my hands or feet.

Select...

I do not have an active stomach ulcer.

Select...

I do not have any mental health conditions that would prevent me from understanding or following the study's requirements.

Select...

I have been diagnosed with non-small cell lung cancer.

Select...

My cancer is at stage IIIB or IV.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 20Eligibility criteria met

Find a Location

Who is running the clinical trial?

Genta IncorporatedLead Sponsor

30 Previous Clinical Trials

1,670 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,153 Total Patients Enrolled

Deborah BracciaStudy ChairGenta Incorporated

Media Library

Docetaxel (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00030641 — Phase 2 & 3

Lung Cancer Clinical Trial 2023: Docetaxel Highlights & Side Effects. Trial Name: NCT00030641 — Phase 2 & 3

Docetaxel (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00030641 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you give me a breakdown of how many sites are participating in this research project?

"Jonsson Comprehensive Cancer Center, UCLA in Los Angeles, Pacific Hematology/Oncology in San Francisco, and Medical Oncology Care Associates in Orange, are some of the 39 hospitals currently running this trial."

Answered by AI

Does this trial have any vacancies for new participants?

"The listed clinical trial on clinicaltrials.gov is no longer recruiting patients. Although, there are 2082 other trials that may be of interest and are currently recruiting. This particular study was first posted on October 1st, 2001 and was last edited on January 3rd, 2014."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

2001. "Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00030641.

All > Lung > Sclc